Inactive Instrument

Cubist Pharmaceuticals Inc Share Price

Stocks

End-of-day quote Nasdaq
- ^USD	-

10/14/10	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/14/09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

10/14/10	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/14/09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
09/14/09	Merck : to take on superbugs with Cubist Pharma buy	RE
09/14/09	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
09/14/09	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
08/14/08	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
06/14/06	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
21/13/21	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

13/15/13	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
20/14/20	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
09/14/09	Cubist Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Cubist Pharmaceuticals Inc.	PR
09/14/09	Cubist Pharmaceuticals : Comments on CUBICIN Patent Litigation	BU
08/14/08	CUBIST PHARMACEUTICALS : ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Cubist Pharmaceuticals, Inc. to Merck	BU

21/14/21	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
21/14/21	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
09/14/09	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
08/14/08	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
08/14/08	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	01/01/1997

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	01/09/2006
Kenneth J. Martin BRD	Director/Board Member	72	25/09/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	+0.61%	+2.88%	+45.63%	+0.39%	8.32TCr
CSL LIMITED	-0.26%	+4.04%	-19.50%	-35.36%	5.95TCr
MODERNA, INC.	+14.36%	+152.27%	+526.55%	+41.90%	6.34TCr
SAMSUNG BIOLOGICS CO.,LTD.	+0.76%	+3.53%	+0.08%	+36.18%	5.29TCr
UCB	+1.86%	+3.13%	+11.49%	+174.36%	4.99TCr
BIOGEN INC.	+1.21%	+3.87%	+61.90%	-16.51%	3.26TCr
INCYTE CORPORATION	+1.36%	+5.06%	+53.04%	+103.13%	2.63TCr
INNOVENT BIOLOGICS, INC.	+8.59%	+10.64%	+13.52%	+212.81%	2.22TCr
SWEDISH ORPHAN BIOVITRUM AB	+3.89%	+1.08%	+61.82%	+112.10%	1.72TCr
Average	+3.60%	+20.50%	+83.84%	+69.89%	4.53TCr
Weighted average by Cap.	+3.47%	+27.36%	+101.60%	+49.18%

Employees

Sector